Keryx Biopharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Keryx Biopharmaceuticals (Boston, MA): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $147.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterBoston, MA
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$147.1M
2024 Medicare Part D Spend$131.5M
2024 Medicaid Spend$15.6M
California HCAI SB 17 Filings4 WAC filings (max 22.7% 2-yr change)